Tempus AI and Daiichi Sankyo have entered a strategic collaboration to apply artificial intelligence and real-world data analytics to the clinical development of an undisclosed antibody drug conjugate in oncology. Chicago-based Tempus will deploy its proprietary AI platform, including the PRISM2 foundation model, to support biomarker discovery and patient stratification for the ADC program. Tokyo-based Daiichi Sankyo, which maintains one of the industry's largest ADC portfolios, will contribute clinical trial and preclinical research data.
Financial terms of the collaboration were not disclosed.
Deal context
The collaboration centers on Tempus's multimodal data and AI capabilities rather than a transfer of drug rights. Tempus operates one of the largest libraries of clinical and molecular data in healthcare, integrating electronic health records, genomic sequencing, and pathology imaging into a unified analytics platform. The company, founded in 2015 and publicly traded on Nasdaq, provides AI-enabled precision medicine tools to both clinicians and pharmaceutical partners.
Under the agreement, the two companies will develop proof-of-concept AI models designed to optimize patient selection for the ADC. Tempus's PRISM2 model combines pathology images with clinical data to generate diagnostic and predictive outputs. These models will be deployed across Tempus's oncology database to produce response maps intended to support patient stratification and benchmarking of potential control arms for future clinical trials.
The specific ADC program was not identified. Daiichi Sankyo's ADC portfolio includes trastuzumab deruxtecan, marketed as Enhertu in partnership with AstraZeneca, and datopotamab deruxtecan, which targets TROP2. The company has additional ADC candidates in clinical development across multiple tumor types. The press release refers to "a novel ADC" without disclosing the biological target, development stage, or indication.